Faskhoudi, M.A.Molaei, P.Sadrkhanloo, M.Orouei, S.Hashemi, M.Bokaie, S.Rashidi, M.Entezari, M.Zarrabi, A.Hushmandi, K.Mirzaei, S.Gholami, M.H.2022-04-062022-04-062022Faskhoudi, M. A., Molaei, P., Sadrkhanloo, M., Orouei, S., Hashemi, M., Bokaie, S., ... & Gholami, M. H. (2022). Molecular landscape of c-Myc signaling in prostate cancer: A roadmap to clinical translation. Pathology-Research and Practice, 153851.0344-0338https://doi.org/10.1016/j.prp.2022.153851https://hdl.handle.net/20.500.12713/2598The c-Myc signaling is a new emerging target in cancer therapy. Activation of c-Myc signaling leads to cancer growth and invasion in vitro and in vivo. The stability of c-Myc can also mediate drug resistance and radioresistance in cancers. The apoptosis inhibition and enhancing cell cycle progression are mediated by c-Myc overexpression. On the other hand, prostate cancer (PC) is the most common cancer in men and causes high death. The present review focuses on c-Myc signaling in PC. The c-Myc overexpression is in favor of PC growth and migration. Upon c-Myc inhibition, apoptosis and cell cycle arrest (G0/G1 phase) occur in PC cells. The c-Myc induces glycolysis in enhancing PC growth. Besides, stability and overexpression of c-Myc can mediate resistance of PC cells to chemotherapy and radiotherapy. The inhibition of c-Myc by both anti-tumor agents and genetic tools suppress PC progression. The miRNAs, lncRNAs, circRNAs and other factors such as PI3K/Akt can act as upstream regulator of c-Myc signaling. The c-Myc can function as independent prognostic and diagnostic factor in PC patients. The c-Myc upregulation is associated with reduced overall survival, clinical stage, lymph node metastasis and undesirable prognosis of PC patients. © 2022 Elsevier GmbHeninfo:eu-repo/semantics/closedAccessBiomarkerC-MycDrug ResistanceNon-coding RNAsProstate CancerReview Article233WOS:0007816944000012-s2.0-85126860539Q210.1016/j.prp.2022.153851Q2